A A van de Loosdrecht
Overview
Explore the profile of A A van de Loosdrecht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
905
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaplan Z, van Leeuwen N, van Klaveren D, Eijkenaar F, Visser O, Posthuma E, et al.
ESMO Open
. 2025 Jan;
10(2):104152.
PMID: 39889323
Background: Acute myeloid leukemia (AML) requires specialized care, particularly when administrating intensive remission induction chemotherapy (ICT). High-volume hospitals are presumed more adept at delivering this complex treatment, resulting in better...
2.
van de Loosdrecht A, Cremers E, Alhan C, Duetz C, In t Hout F, Visser-Wisselaar H, et al.
Leukemia
. 2024 Jan;
38(4):840-850.
PMID: 38297135
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients...
3.
Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji R, Sekeres M, et al.
Leukemia
. 2020 Jun;
35(3):835-849.
PMID: 32595214
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or...
4.
Cruijsen M, van der Velden W, de Haan A, Klein S, Hoogendoorn M, Tromp Y, et al.
Leuk Lymphoma
. 2020 Jun;
61(11):2752-2755.
PMID: 32530341
No abstract available.
5.
Platzbecker U, Fenaux P, Ades L, Giagounidis A, Santini V, van de Loosdrecht A, et al.
Blood
. 2018 Nov;
133(10):1020-1030.
PMID: 30404811
The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient response to treatment challenging. In 2006, the International Working Group (IWG) proposed a revision to previously published standardized response criteria...
6.
van Spronsen M, Witte B, Ossenkoppele G, Westers T, van de Loosdrecht A
Eur J Cancer
. 2017 Jan;
72:269-271.
PMID: 28057399
No abstract available.
7.
Garelius H, Johnston W, Smith A, Park S, de Swart L, Fenaux P, et al.
J Intern Med
. 2016 Dec;
281(3):284-299.
PMID: 27926979
Background: The EUMDS registry is an unique prospective, longitudinal observational registry enrolling newly diagnosed patients with lower-risk myelodysplastic syndrome (MDS) from 17 European countries from both university hospitals and smaller...
8.
Dinmohamed A, van Norden Y, van de Loosdrecht A, Jongen-Lavrencic M
Leukemia
. 2016 May;
30(8):1795-6.
PMID: 27198054
No abstract available.
9.
Chen S, Zambetti N, Bindels E, Kenswill K, Mylona A, Adisty N, et al.
Leukemia
. 2016 Apr;
30(9):1938-42.
PMID: 27109510
No abstract available.
10.
Alhan C, Westers T, Cremers E, Cali C, Witte B, Ossenkoppele G, et al.
Leukemia
. 2015 Oct;
30(3):658-65.
PMID: 26503643
The prognosis of myelodysplastic syndromes (MDS) is currently estimated by using the revised International Prognostic Scoring System (IPSS-R). Several studies have shown that further refinement of prognostication for MDS can...